<DOC>
	<DOCNO>NCT01510704</DOCNO>
	<brief_summary>To assess efficacy safety different dos APD421 prevention post-operative nausea vomiting ( PONV ) adult patient moderate high-risk PONV . Patients must undergo elective surgery general anaesthesia ( hysterectomy ( surgical technique ) , cholecystectomy ( surgical technique ) `` '' elective surgery schedule last least one hour induction anaesthesia ) , require least one overnight stay hospital , least 2 follow risk factor PONV : Past history PONV and/or motion sickness ; Non-smoking status ; Female gender ; Planned opiate use post-operative analgesia .</brief_summary>
	<brief_title>Phase II Dose-ranging Study APD421 PONV</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Postoperative Nausea Vomiting</mesh_term>
	<criteria>Inclusion criterion 1 . Male female patient ≥ 18 year age 2 . Ability willingness give write informed consent 3 . Patients undergo elective surgery general anaesthesia require least one overnight stay hospital either : 1 . Hysterectomy ( surgical technique ) 2 . Cholecystectomy ( surgical technique ) 3 . Other elective surgery require overnight admission hospital schedule last least 1 hour induction anaesthesia 4 . Patients least 2 follow risk factor PONV : 1 . Past history PONV and/or motion sickness 2 . Habitual nonsmoking status 3 . Female sex 4 . Expected receive opioid analgesia postoperatively 5 . American Society Anesthesiologists ( ASA ) risk score IIII 6 . Adequate cardiac , hepatic renal function QTc interval &lt; 500 m Alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) &lt; 5 x upper limit normal ( ULN ) Bilirubin &lt; 3 x ULN Creatinine &lt; 2 x ULN 7 . Adequate haematological function Haemoglobin ≥ 9 g/dL White blood count ≥ 3.0 x 109/L Platelet count ≥ 100 x 109/L 8 . For female childbearing potential : ability willingness use highly effective form contraception ( e.g. , abstinence sexual intercourse , surgical sterilisation ( subject partner ) doublebarrier method contraception either intrauterine device ( IUD ) occlusive cap spermicide , conjunction partner 's use condom ) date screen least 48 hour administration study drug . Exclusion Criteria 1 . Patients undergo outpatient/day case surgery 2 . Patients undergo surgery patient expect remain ventilated period surgery 3 . Patients undergo intrathoracic , transplant central nervous system surgery 4 . Patients receive local anaesthetic/regional neuraxial ( intrathecal epidural ) block 5 . Patients expect need naso oralgastric tube situ surgery complete 6 . Patients receive active ingredient APD421 indication within last 2 week 7 . Patients allergic active ingredient excipients APD421 8 . Patients preexist vestibular disorder history dizziness 9 . Patients preexist nausea vomit 24 hour surgery 10 . Patients treat regular antiemetic therapy include corticosteroid 11 . Patients treated medication could induce torsades de pointes , include Class Ia antiarrhythmic agent quinidine , disopyramide , procainamide ; Class III antiarrhythmic agent amiodarone sotalol ; medication bepridil , cisapride , thioridazine , methadone , IV erythromycin , IV vincamine , halofantrine , pentamidine , sparfloxacin 12 . Patients treat levodopa 13 . Patients pregnant breast feed 14 . Patients history alcohol abuse 15 . Patients preexist , clinically significant cardiac arrhythmia 16 . Patients diagnose Parkinson 's disease 17 . Patients receive anticancer chemotherapy previous 4 week 18 . Patients history epilepsy 19 . Any concurrent disease illness , opinion investigator make patient unsuitable study 20 . Patients participate previous study within last 28 day ( French site : Patients participate previous study within last 6 month , require national local regulation )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>